Sensitive and specific detection of the non-human sialic acid N-Glycolylneuraminic acid in human tissues and biotherapeutic products

PLoS ONE

Volumn 4, Issue 1, 2009, Pages

  Diaz, Sandra L ^a   Padler Karavani, Vered ^a   Ghaderi, Darius ^a   Hurtado Ziola, Nancy ^b   Yu, Hai ^c   Chen, Xi ^c   Brinkman Van der Linden, Els C M ^d   Varki, Ajit ^a   Varki, Nissi M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Gc Free Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; IMMUNOGLOBULIN Y; MONOCLONAL ANTIBODY; N GLYCOLOYLNEURAMINIC ACID; POLYCLONAL ANTIBODY; SIALIC ACID; SIALOGLYCOPROTEIN; BIOLOGICAL PRODUCT; IMMUNOGLOBULIN; N (O ACETYL)GLYCOLOYLNEURAMINIC ACID; N-(O-ACETYL)GLYCOLOYLNEURAMINIC ACID; POLYSACCHARIDE; SIALIC ACID DERIVATIVE;

ARTICLE; CARBOHYDRATE ANALYSIS; CELL LINE; CHICKEN; CHIMPANZEE; CONTROLLED STUDY; ELUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; ANIMAL; CHEMISTRY; CLINICAL CHEMISTRY; CULTURE MEDIUM; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MUTATION; REPRODUCIBILITY;

ANIMALIA; MAMMALIA; MUS; PAN;

ANIMALS; BIOLOGICAL PRODUCTS; CHEMISTRY, CLINICAL; CHICKENS; CULTURE MEDIA, SERUM-FREE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MICE; MUTATION; POLYSACCHARIDES; REPRODUCIBILITY OF RESULTS; SIALIC ACIDS;

EID: 58749102075     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004241     Document Type: Article

References (44)

1. Varki A (2001) Loss of N-Glycolylneuraminic acid in Humans Mechanisms, Consequences and Implications for Hominid Evolution. Am J Phys Anthropol 4: Suppl 33: 54-69.
2. Varki A (2008) Multiple changes in sialic acid biology during human evolution. Glycoconj J in press.
3. Zhu A, Hurst R (2002) Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9: 376-381.
4. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, et al. (2003) Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A 100: 12045-12050.
5. Padler-Karavani V, Yu H, Cao H, Ghokhawala H, Karp F, et al. (2008) Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 18: 818-830.
6. Martin MJ, Muotri A, Gage F, Varki A (2005) Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 11: 228-232.
7. Bytes E, Paton AW, Paton JC, Loffing JC, Smith DF, et al. (2008) Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature 456: 648-652.
8. Malykh YN, Schauer R, Shaw L (2001) N-glycolylneuraminic acid in human tumours. Biochimie 83: 623-634.
9. Hedlund M, Padler-Karavani V, Varki NM, Varki A (2008) Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci U S A 105: 18936-18941.
10. Hermentin P, Witzel R, Viegenthart JFG, Kamerling JP, Nimtz M, et al. (1992) A strategy for the mapping of N-glycans by high-pH anion-exchange chromatography with pulsed amperometric detection. Anal Biochem 203: 281-289.
11. Noguchi A, Mukuria CJ, Suzuki E, Naiki M (1995) Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains-of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J Biochem (Tokyo) 117: 59-62.
12. Rohrer JS, Thayer J, Weitzhandler M, Avdalovic N (1998) Analysis of the N-acetyineuraminic acid and N-glycolylneuraminic acid contents of glycoproteins by high-pH anion-exchange chromatography with pulsed amperometric detection (HPAEC/PAD). Glycobiology 8: 35-43.
13. Raju TS, Briggs JB, Borge SM, Jones AJS (2000) Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10: 477-486.
14. Nasonkin IO, Koliatsos VE (2006) Nonhuman sialic acid Neu5Gc is very low in human embryonic stem cell-derived neural precursors differentiated with B27/N2 and noggin: Implications for transplantation. Exp Neurol 201: 525-529.
15. Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, et al. (2007) N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 25: 197-202.
16. Montesino R, Toledo JR, Sanchez O, Sanchez A, Harvey DJ, et al. (2008) Monosialylated biantennary N-glycoforms containing GalNAc-GlcNAc antennae predominate when human EPO is expressed in goat milk. Arch Biochem Biophys 470: 163-175.
17. Kim YG, Gil GC, Harvey DJ, Kim BG (2008) Structural analysis of alpha-Gal and new non-Gal carbohydrate epitopes from specific pathogen-free miniature pig kidney. Proteomics 8: 2596-2610.
18. Hashii N, Kawasaki N, Nakajima Y, Toyoda M, Katagiri Y, et al. (2007) Study on the quality control of cell therapy products. Determination of N-glycolylneuraminic acid incorporated into human cells by nano-flow liquid chromatography/Fourier transformation ion cyclotron mass spectrometry. J Chromatogr A 1160: 263-269.
19. Miyake M, Ito M, Hitomi S, Ikeda S, Taki T, et al. (1988) Generation of two murine monoclonal antibodies that can discriminate X-glycolyl and N-acetyl neuraminic acid residues of GM2 gangliosides. Cancer Res 48: 6154-6160.
20. Tai T, Kawashima I, Furukawa K, Lloyd KO (1988) Monoclonal antibody R24 distinguishes between different N-acetyl- and N-glycolylneuraminic acid derivatives of ganglioside GD3. Arch Biochem Biophys 260: 51-55.
21. Ohashi Y, Sasabe T, Nishida T, Nishi Y, Higashi H (1983) Hanganutziu-Deicher heterophile antigen in human retinoblastoma cells. Am J Ophthalmol 96: 321-325.
22. Higashi H, Nishi Y, Fukui Y, Ikuta K, Ueda S, et al. (1984) Tumor-associated expression of glycosphingolipid Hanganutziu-Deicher antigen in human cancers. Gann 75: 1025-1029.
23. Higashi H, Hirabayashi Y, Fukui Y, Naiki M, Matsumoto M, et al. (1985) Characterization of N-glycolylneuraminic acid-containing gangliosides as tumor-associated Hanganutziu-Deicher antigen in human colon cancer. Cancer Res 45: 3796-3802.
24. Hirabayashi Y, Kasakura H, Matsumoto M, Higashi H, Kato S, et al. (1987) Specific expression of unusual GM2 ganglioside with Hanganutziu-Deicher antigen activity on human colon cancers. Jpn J Cancer Res 78: 251-260.
25. Higashi H, Sasabe T, Fukui Y, Maru M, Kato S (1988) Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn J Cancer Res 79: 952-956.
26. Fukui Y, Maru M, Ohkawara K, Miyake T, Osada Y, et al. (1989) Detection of glycoproteins as tumor-associated Hanganutziu-Deicher antigen in human gastric cancer cell line, NUGC4. Biochem Biophys Res Commun 160: 1149-1154.
27. Gathuru JK, Higashi H, Kato S, Usuba O, Naiki M (1989) Use of biotinylated antibody for the assay of Hanganutziu-Deicher antibodies and antigens in fluids and tissues from cancer patients. Jpn J Vet Res 37: 71-83.
28. Saida T, Ikegawa S, Takizawa Y, Kawachi S (1990) Immumohistochemical detection of heterophile Hanganutziu-Deicher antigen in human malignant melanoma. Arch Dermatol Res 282: 179-182.
29. Kawachi S, Saida T (1992) Analysis of the expression of Hanganutziu-Deicher (HD) antigen in human malignant melanoma. J Dermatol 19: 827-830.
30. Mukuria CJ, Noguchi A, Suzuki E, Naki M (1994) Potential use of specific human and chicken antibodies for detection of Hanganutziu-Deicher antigen(s) in sera of cancer patients. Jpn J Med Sci Biol 47: 253-264.
31. Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD, et al. (2007) N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol Cell Biol 27: 4340-4346.
32. Yu H, Chokhawala HA, Varki A, Chen X (2007) Efficient chemoenzymatic synthesis of biotinylated human serum albumin-sialoglycoside conjugates containing O-acetylated sialic acids. Org Biomol Chem 5: 2458-2463.
33. Higashi H, Naiki M, Matuo S, Okouchi K (1977) Antigen of "serum sickness" type of heterophile antibodies in human sera: indentification as gangliosides with N-glycolylneuraminic acid. Biochem Biophys Res Commun 79: 388-395.
34. Padlan EA, Kabat EA (1988) Model-building study of the combining sites of two antibodies to alpha(1->6)dextran. Proc Natl Acad Sci USA 85: 6885-6889.
35. Sigurskjold BW, Bundle DR (1992) Thermodynamics of oligosaccharide binding to a monoclonal antibody specific for a Salmonella O-antigen point to hydrophobic interactions in the binding site. J Biol Chem 267: 8371-8376.
36. Lee M, Lloyd P, Zhang X, Schallhorn JM, Sugimoto K, et al. (2006) Shapes of antibody binding sites: qualitative and quantitative analyses based on a geomorphic classification scheme. J Org Chem 71: 5082-5092.
37. Houliston RS, Yuki N, Hirama T, Khieu NH, Brisson JR, et al. (2007) Recognition characteristics of monoclonal antibodies that are cross-reactive with gangliosides and lipooligosaccharide from Campylobacter jejuni strains associated with Guillain-Barre and Fisher syndromes. Biochemistry 46: 36-44.
38. Hara S, Yamaguchi M, Takemori Y, Nakamura M, Ohkura Y (1986) Highly sensitive determination of N-acetyl- and N-glycolylneuraminic acids in human serum and urine and rat serum by reversed-phase hquid chromatography with fluorescence detection. J Chromatogr 377: 111-119.
39. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, et al. (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9: 1909-1917.
40. Nichols W, Lardenoije R, Ledwith B, Brower K, Manam S, Vogels R, Kaslow D, Zuidgeest D, Bett A, Chen L, van der Kaaden M, Galloway S, Hill R, Machotka S, Anderson C, Lewis J, Martinez D, Lebron J, Russo C, Valerio D, Bout A (2002) Propagation of Adenoviral Vectors: Use of PER.C6® Cells, 2002. In "Adenoviral Vectors for Gene Therapy", pp 129-166, Elsevier Science, USA.
41. Lewis JA, Brown EL, Duncan PA (2006) Approaches to the release or a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol (Basel) 123: 165-76; discussion 183-97.
42. Jones D, Kroos N, Anema R, van Montfort B, Vooys A, et al. (2003) High-level expression or recombinant IgG in the human cell fine per.c6. Biotechnol Prog 19: 163-168.
43. Yallop CA, Crowley J, Cote J, Hegmans-Brouwer K, Lagerwerf F, Gagne R, Martin JC, Oosterhuis N, Opstelten DJ, Bout A. PER.C6 cells for the manufacture of biophamaceutical proteins. In "Modern Biopharmaceuticals. Volume 3. Design, Development and Optimization", pp 779-807, Wiley-VCH: Germany.
44. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, et al. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358: 1109-1117.